Navigation Links
Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
Date:4/21/2009

_new">www.aacr.org. A copy of the posters presented at AACR may be obtained by contacting the Company.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. We are developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. We are also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company is also engaged in business development activities that include evaluating compounds and companies for in-licensing or acquisition, as well as seeking strategic relationships for our product candidates and for our company. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for KRX-0401, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- Verenium Corporation (Nasdaq: VRNM ), a leading ... of high-performance enzymes, today announced that Jeffrey ... two upcoming conferences. (Logo: http://photos.prnewswire.com/prnh/20120924/MM79973LOGO ) ... Annual Marcum LLP Microcap Conference on Thursday, May 30, ... City.  The presentation is scheduled to begin at 4:30 ...
(Date:5/23/2013)... 23, 2013 Pusan National University Yangsan ... biotherapeutics and contract research company focused on research ... announced today a publication reporting the induction of ... oncolytic and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; Jennerex ... in the May 15 th , 2013 issue ...
(Date:5/23/2013)... May 23, 2013 African ... tracing for people of African descent, today announced ... offering. For people of all races, myDNAmix determines ... five distinct populations: Indigenous Americas (Native American), East ... Subcontinent. , Originally launched in late ...
(Date:5/23/2013)... 2013 Bed bugs compromised Penn ... already confirmed it. Meanwhile, My Cleaning Products offered complimentary samples ... fight the pests without using harmful chemical elements. , ... 2013, the affected building was actually a dormitory , ... said made on May 13 and bed bug presence was ...
Breaking Biology Technology:Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 2AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 3Penn State Dorm Infested with Bed Bugs, My Cleaning Products Offers Complimentary Sample of Bed Bug Spray to Help Bed Bug Victims 2
... Harriet L. Robinson, Ph.D., Chief Scientific Officer at ... in the development of HIV/AIDS vaccines, announced the results ... step closer to a vaccine that protects against multiple ... by Dr. Robinson during a presentation in Seattle at ...
... local product advancements and a strong 2012 research pipeline ... growth, Pioneer President Paul E. Schickler told ... "Global trends like an expanding middle class ... demand for food and require constant innovation, global science ...
... March 7, 2012 Palatin Technologies, Inc. (NYSE Amex: ... the 24th Annual ROTH OC Growth Stock Conference on Tuesday, ... will be held at the Ritz Carlton Laguna Niguel in ... and Chief Executive Officer of Palatin Technologies, will provide an ...
Cached Biology Technology:GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI) 2GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI) 3GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI) 4DuPont Leader Overviews 2012 Seed Research Pipeline with Investors 2DuPont Leader Overviews 2012 Seed Research Pipeline with Investors 3
(Date:5/21/2013)... Biologists have known for a long time that some ... well understood, particularly for plants. But it may be ... Australian National University and the U. S. National Evolutionary ... published 21 May in the journal Nature Communications ... faster-changing genomes. , Drawing from a database of global ...
(Date:5/21/2013)... "place" is increasingly being considered in the management ... new resource that can help them recognize and ... places in their lives. , Place-Based Conservation: ... co-edited by the Pacific Northwest Research Station,s Linda ... to conservation. The book is published by Springer ...
(Date:5/21/2013)... cells in the blood often jump into action ... that can fight off illness. But repeated infections ... leading to the development of serious blood conditions ... led by biologists at the California Institute of ... the molecule microRNA-146a (miR-146a) acts as a critical ...
Breaking Biology News(10 mins):Small but speedy: Short plants live in the evolutionary fast lane 2Keeping stem cells strong 2
... issue of Sports Technology , published by ... the gap between able-bodied athletes and para-athletes, with ... first article, entitled "Biomechanics of double transtibial amputee ... al., compares the sprinting mechanics data of able-bodied ...
... patients with a particularly aggressive form of skin cancer ... from simply hearing that diagnosis, might amplify the progression ... that infers this also suggests that the use of ... of those tumors and therefore improve these patients, quality ...
... Entrust, Inc. (Nasdaq: ENTU ), a world leader in ... fiscal quarter and year ended December 31, 2008.Fourth-Quarter 2008, ... of $24.9 million, a decrease of 7% over Q4 2007; total ... million, an increase of 5%, adjusting for currency , ...
Cached Biology News:Stress may hasten the growth of melanoma tumors 2Stress may hasten the growth of melanoma tumors 3Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 2Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 3Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 4Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 5Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 6Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 7Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 8Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 9Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 10Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 11Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 12Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 13Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 14Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 15Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 16Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 17Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 18Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 19Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 20Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 21
Mycoplasma and virus tested...
... MagicMark and MagicMark XP Western Protein ... and convenient protein molecular weight estimation ... protein contains an IgG binding site, ... antibody-conjugate reagents used to detect your ...
... Immunogen: Synthetic peptide derived ... JAB1 (Jun activation domain-binding protein ... for the JAB1 protein. ... Jurkat cell lysates). Applications: ...
...
Biology Products: